Medifast (NYSE:MED – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.100-0.650 for the period, compared to the consensus estimate of -0.180. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.0 million.
Medifast Trading Up 1.4 %
NYSE MED traded up $0.27 during trading hours on Tuesday, reaching $19.08. 290,083 shares of the company traded hands, compared to its average volume of 390,096. Medifast has a 12 month low of $17.07 and a 12 month high of $76.42. The stock has a market capitalization of $208.74 million, a PE ratio of 7.62 and a beta of 1.13. The company has a 50 day moving average of $18.43 and a two-hundred day moving average of $21.00.
Medifast (NYSE:MED – Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The specialty retailer reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.50. Medifast had a net margin of 3.81% and a return on equity of 25.77%. The firm had revenue of $140.16 million for the quarter, compared to the consensus estimate of $135.45 million. During the same period in the prior year, the firm posted $2.12 EPS. On average, equities research analysts anticipate that Medifast will post 1.12 earnings per share for the current year.
Wall Street Analyst Weigh In
Read Our Latest Analysis on MED
About Medifast
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
See Also
- Five stocks we like better than Medifast
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Insider Buying Signals Upside for These 3 Stocks
- Dividend Payout Ratio Calculator
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
- How to Plot Fibonacci Price Inflection Levels
- NXP Semiconductors Nears Rock Bottom: A Buy Signal Is Expected
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.